Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
YIV-906 + Sorafenib for Liver Cancer
Recruiting0 awardsPhase 2
Flushing, New York
This trial tests if adding YIV-906 to the standard liver cancer drug sorafenib helps patients with advanced liver cancer linked to Hepatitis B. YIV-906 is a herbal capsule that boosts the immune system and protects the gut, while sorafenib stops cancer cells from growing.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service